Company announcement, Helsinki, 20 May 2019 at 9.30 AM
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and marketing pioneering, navigated, personalized, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), has completed a rights issue which ended on 24 April 2019 in Sweden and on 26 April 2019 in Finland. Upon approval of subscriptions in such rights issue, the Board of Directors allocated in total 15,601,167 special rights to shares (“Offer Warrants”) to subscribers of its shares. The Offer Warrants entitle to subscribe to a maximum of 15,601,167 shares of the Company according to the terms of such Offer Warrants. The Offer Warrants were expected to be delivered to such subscribers approximately during week 21, 2019.
The Company now announces that the Offer Warrants are delivered to the subscribers today on 20 May 2019, and the trading of such Offer Warrants will begin on First North Finland and First North Sweden on 20 May 2019.
Martin Jamieson, CEO
Further information is available on the website www.nexstim.com, or by contacting:
Martin Jamieson, Chairman and CEO
+44 771 516 3942
Sisu Partners Oy (Certified Adviser)
+ 358 40 842 4479
Citigate Dewe Rogerson
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
About Nexstim Plc
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology - a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated, transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.
Nexstim's NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.